A phase 2 trial of avelumab in men with aggressive-variant or neuroendocrine prostate cancer

BACKGROUND: Men with progressive neuroendocrine or aggressive-variant metastatic prostate cancer (NEPC/AVPC) have a poor prognosis and limited treatment options, and immunotherapy has not been tested in such patients. METHODS: We conducted an open label single center phase 2 trial (NCT03179410) of m...

Descripción completa

Detalles Bibliográficos
Autores principales: Brown, Landon C., Halabi, Susan, Somarelli, Jason A., Humeniuk, Michael, Wu, Yuan, Oyekunle, Taofik, Howard, Lauren, Huang, Jiaoti, Anand, Monika, Davies, Catrin, Patel, Prekshaben, Staats, Janet, Weinhold, Kent J., Harrison, Michael R., Zhang, Tian, George, Daniel J., Armstrong, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923335/
https://www.ncbi.nlm.nih.gov/pubmed/35292724
http://dx.doi.org/10.1038/s41391-022-00524-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8923335/
https://www.ncbi.nlm.nih.gov/pubmed/35292724
http://dx.doi.org/10.1038/s41391-022-00524-7

Ejemplares similares